Drug Trial Radar · NCT04495179
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 4, 2020
Primary completion
Nov 1, 2021
Study completion Aug 8, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jul 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 150 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
- Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions
AZD4635Drug
Subjects will receive AZD4635 orally daily
DurvalumabDrug
Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
CabazitaxelDrug
Subjects will receive intravenous cabazitaxel every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression Free Survival (rPFS) in Each Arm Separately to Determine the Efficacy of AZD4635 Plus Durvalumab and of AZD4635 Plus Durvalumab Plus Cabazitaxel in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)Time frame: From first dose to first documented progression or death from any cause (whichever comes first) (approximately 1 year)
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Sacramento, California
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
St Louis, Missouri
Research Site
Winston-Salem, North Carolina
Research Site
Brasschaat, Belgium
Research Site
Ghent, Belgium
Research Site
Bordeaux, France
Research Site
Villejuif, France
Research Site
Goyang-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Hospitalet deLlobregat, Spain
Research Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.